Bpoc
BPOC is the public-facing name of Beecken Petty O’Keefe & Company, LLC, a Chicago-based private equity firm founded in 1996. It invests in founder-owned healthcare companies in the lower middle market and states that it considers majority or active minority positions.
What stands out about Bpoc
BPOC publicly describes a U.S. healthcare investment strategy focused on founder-owned lower-middle-market companies. Its stated criteria include EBITDA of at least $3M, $25M–$100M equity investments, majority or active minority positions, strong founders and management, management investment alongside BPOC, quality and compliance focus, historical growth, and defensible market positions.[1][2][8]
What does Bpoc invest in?
BPOC is the public-facing name of Beecken Petty O’Keefe & Company, LLC, a Chicago-based private equity firm founded in 1996. BPOC describes itself as a private equity investor in founder-owned healthcare companies in the lower middle market.
BPOC states that it is an investment adviser registered with the United States Securities and Exchange Commission under the Investment Advisers Act of 1940. Its public materials describe a founder-partnership approach supported by institutional rigor, experienced operating resources, and partner-led value-creation plans.[1][2][8]
BPOC states that it invests in companies addressing cost, access, and quality challenges in the U.S. healthcare market and seeks to build enduring healthcare leaders. Its approach includes support for organic and inorganic growth, with management investment alongside BPOC identified among its criteria.[1][2]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
Published criteria: BPOC publicly lists EBITDA of at least $3M and $25M–$100M equity investments among its investment criteria. It also states that it considers majority or active minority positions.[2]
What should a business owner evaluate before considering a transaction with Bpoc?
Owners evaluating BPOC can compare the company’s stated healthcare mandate, EBITDA threshold, equity-investment range, and majority or active minority approach with their own transaction objectives. BPOC also identifies management investment alongside the firm and a founder-partnership model supported by operating resources.
The applicable investment vehicle and offering documents should be confirmed directly. The cited regulatory-information page directs readers to private placement memoranda and other offering documents for fund investment objectives, risks, fees, and expenses.[1][2][8]
Which BPOC fund or investment vehicle would finance the transaction, and which fund-level investment objectives, risks, fees, and expenses would apply
How would BPOC’s majority or active minority approach apply to the proposed transaction, including the expected management investment alongside BPOC
Which operating resources and partner-led value-creation plans would be relevant to the company
What companies does Bpoc target?
BPOC publicly lists EBITDA of at least $3M and $25M–$100M equity investments among its investment criteria. It states that it considers majority or active minority positions and looks for strong founders and management, management investment alongside BPOC, a quality and compliance focus, attractive historical growth, and defensible market positions.[2]
BPOC identifies four healthcare focus areas: outsourced services; products and distribution; providers; and pharmacy and pharma services. The firm’s stated examples include healthcare services and technology, medical products and supplies, clinical staffing, primary care, dental services, pharmacy management, clinical research, and specialty distribution.[2]
BPOC states that its investment strategy addresses the U.S. healthcare market.[2]
BPOC describes support for organic and inorganic growth. Its official portfolio materials list current and realized healthcare investments, while its full investment list contains additional investments. The sources cited for this profile do not establish a separate platform-versus-add-on policy.[1][3][4]
BPOC’s official full-investments page lists current and realized healthcare investments including Alliance Clinical Network, Bond Orthodontic Partners, ClareMedica Health Partners, Health Management Associates, Medicus Healthcare Solutions, Praxis Packaging Solutions, and Southeast Primary Care Partners. Its portfolio page states that selected active and former investments illustrate investments fitting its current healthcare strategy.[3][4]
On August 24, 2026, BPOC announced strategic investments in Master Medical Equipment and ReNew Biomedical, sister companies serving pre-hospital and post-acute markets with equipment distribution, rental, repair, and maintenance services.
On June 2, 2026, Alliance Clinical Network and Atlas Clinical Research announced the closing of their strategic merger; BPOC continued to support the combined clinical research platform alongside Amulet Capital Partners. On April 7, 2026, BPOC announced completion of the sale of Midwest Products & Engineering to Graham Partners after BPOC’s majority ownership beginning in 2019.[5][6][7]
What is not clear from Bpoc's public investment criteria?
The cited BPOC regulatory-information page states that information about investing in BPOC funds is available through private placement memoranda and other offering documents containing investment objectives, risks, fees, and expenses. Those fund-level terms are not presented on that page as public website disclosures.[8]
Questions to ask when evaluating Bpoc as a buyer or investment partner
Which BPOC fund or investment vehicle would finance the transaction, and which fund-level investment objectives, risks, fees, and expenses would apply?
How would BPOC’s majority or active minority approach apply to the proposed transaction, including the expected management investment alongside BPOC?
Which operating resources and partner-led value-creation plans would be relevant to the company?
How would BPOC support organic and inorganic growth for the company?
Sources & research notes
- Official website / firm overview
- Services / capabilities
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Structure / regulatory context
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.